DarioHealth Announces Independent Aon Analysis that Supports Estimated 2.5%-7.2% In-Year Reduction in Total Healthcare Costs

The review estimates savings across total covered-population healthcare spending, but relies on materials identified or provided by Dario.

Rhea-AI Summary

DarioHealth (DRIO) announced an Aon review supporting estimated annual healthcare cost reductions of 2.5% to 7.2% across a covered population.

The estimate measures total healthcare spending, not just participant spending. For a representative 20,000-life population, estimated savings are roughly $3.8 million to $10.8 million annually. Aon estimated that managing multiple conditions and providing physician access may add 1.6 to 2.8 percentage points of savings. A component study found $5,077 in annual savings and 23.5% fewer inpatient discharges per Dario user with type 2 diabetes versus matched non-users.

The review covered 17 studies identified by Dario, including independent and Dario-sponsored research. Aon did not independently verify underlying data, audit studies or evaluate all available evidence. Its findings support associations rather than guaranteed outcomes; results vary by population and other factors.

Positive

• Minor point. Forward-looking: it has not happened yet and may not happen.Aon review supports estimated 2.5% to 7.2% annual healthcare cost reductions across a covered population.
• Minor point. Forward-looking: it has not happened yet and may not happen.Multi-condition management and physician access may add 1.6 to 2.8 percentage points of healthcare cost savings.
• Minor pointComponent study found $5,077 annual savings per Dario user with type 2 diabetes versus matched non-users.
• Minor pointComponent study found 23.5% fewer inpatient discharges per Dario user with type 2 diabetes versus matched non-users.

Negative

• Minor pointReview relied on Dario-identified or supplied materials, without independent data verification, study audits or evaluation of all evidence.
• Minor point. Forward-looking: it has not happened yet and may not happen.Estimated savings depend on population, utilization and disease burden; individual organizations' outcomes will vary.

Key Figures

Estimated annual healthcare cost reduction: 2.5% to 7.2% Estimated annual savings: $3.8 million to $10.8 million Additional potential cost savings: 1.6 to 2.8 percentage points +3 more

Estimated annual healthcare cost reduction

2.5% to 7.2%

Across a covered population, measured against total healthcare spend

Estimated annual savings

$3.8 million to $10.8 million

Representative 20,000-life population

Additional potential cost savings

1.6 to 2.8 percentage points

Estimated contribution from multiple-condition management and physician access

Annual savings per Dario user

$5,077

Component study of users with type 2 diabetes versus matched non-users

Fewer inpatient discharges

23.5%

Per Dario user with type 2 diabetes versus matched non-users

Studies evaluated

17 studies

Studies identified by Dario and evaluated by Aon

Key Terms

propensity score-matching methodologies, randomized controlled trials

2 terms

propensity score-matching methodologies technical

"real-world studies using propensity score-matching methodologies"

A group of statistical techniques used in observational studies to create comparable groups by matching individuals (or other units) with similar propensity scores — the estimated probability that each unit received the treatment or exposure given observed characteristics. Researchers first model the propensity score from measured covariates, then pair or group treated and untreated units with similar scores so that outcome differences are less likely to be driven by those measured covariates; variants include one-to-one matching, caliper matching, and weighting by the propensity score. These methods can reduce bias from observed confounders but cannot adjust for unmeasured variables, so their validity depends on the quality and completeness of the covariate data and on diagnostics that check how well matching balanced those covariates.

randomized controlled trials medical

"together with randomized controlled trials conducted by Dario and third parties"

Randomized controlled trials are studies where participants are randomly assigned to receive either a new treatment or a comparison (such as a standard treatment or placebo), so outcomes can be fairly compared like flipping a coin to decide teams. For investors, they matter because they provide the most reliable evidence about whether a drug, device or intervention actually works and is safe, which influences regulatory approval, market demand and the financial outlook of companies developing them.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

A component study of the independent review by Aon found $5,077 in annual savings and 23.5% fewer inpatient discharges per Dario user with type 2 diabetes versus matched non-users

Evaluation of 17 studies estimates $3.8 million to $10.8 million in annual savings for a 20,000-life population

Aon estimates an additional 1.6 to 2.8 percentage points of potential healthcare cost savings as a result of providing direct access to physicians while simultaneously managing multiple chronic conditions, for potential total of 10% annual savings

Independent analysis finds that evidence supports the economic value of Dario's multi-condition digital health platform for payers including employers, health plans, health systems and accountable care organizations (ACOs)

NEW YORK, Oct. 6, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leading AI-powered healthcare technology company transforming the management of chronic conditions, today announced the results of a review titled "An Independent Review of Evidence Supporting DarioHealth's Clinical and Cost-Savings Impact" conducted by the Managed Care Services Team of Aon plc ("Aon"), a leading global professional services firm.

Based upon its review of data provided by Dario and published studies identified by Dario, Aon's Managed Care Services Team concluded that the evidence reviewed supports an estimated reduction in total healthcare costs of 2.5% to 7.2% annually across a covered population – measured against total healthcare spend, not only the spend of program participants. For a representative 20,000-life population, that is roughly $3.8 million to $10.8 million a year, depending on disease burden and other factors.

From its analysis of the materials reviewed, Aon concluded that the estimates may be conservative because they exclude two elements of Dario's current service model: management of multiple conditions and providing access to physicians. Aon estimated that these factors may contribute an additional 1.6 to 2.8 percentage points of healthcare cost savings.

The estimate rests on data provided by Dario and Aon's evaluation of 17 studies identified by Dario spanning cardiometabolic, musculoskeletal and behavioral health, including independently conducted research as well as Dario-sponsored studies. Aon observed that the results reported in the reviewed studies were broad and consistent across the identified clinical, behavioral, utilization and cost measures.  The evidence portfolio includes real-world studies using propensity score-matching methodologies together with randomized controlled trials conducted by Dario and third parties. Based on the materials reviewed, Aon concluded the evidence supports an association between Dario's services and meaningful clinical, financial and utilization improvements, and that the observed effects may be generalizable to real-world populations.

"Self-funded employers, health plans and risk-bearing providers, including ACOs, are being asked to cut healthcare costs this year, not in three years" said Erez Raphael, Chief Executive Officer of Dario. "Aon reviewed the data and studies we provided and concluded that the evidence reviewed supports an association between Dario's services and meaningful clinical and financial outcomes in real-world settings.  We believe these findings further demonstrate the value of Dario's approach to chronic condition management."

Important Limitations of Aon's Review

Aon's review was limited to published data, studies, and other materials identified or provided by Dario. Aon did not conduct an independent verification of underlying data, audit the studies, or evaluate all available evidence relating to Dario's services. Aon's conclusions are based solely on the materials reviewed. Outcomes for individual organizations will vary based on their populations, utilization patterns, disease burden and other factors. Aon's conclusions are not a prediction or guarantee of future results and should not be construed as a guarantee of any particular outcome for any specific customer.

About DarioHealth Corp.

DarioHealth (NASDAQ: DRIO) is an AI-powered healthcare technology company helping health plans, health systems and employers improve health outcomes while lowering the cost of care. The Company's integrated platform combines connected devices, personalized member engagement, AI-driven insights and provider-backed clinical care to support people living with conditions including diabetes, hypertension, weight management, musculoskeletal and behavioral health needs.

Powered by more than 13 billion proprietary longitudinal healthcare data points collected over more than a decade, Dario's AI platform personalizes care at the individual member level by analyzing biometric, clinical and behavioral data to deliver more timely and effective interventions. By combining engagement, clinical intelligence and care delivery within a single platform, Dario helps customers address multiple chronic conditions through one solution.

Cautionary Note Regarding Forward-Looking Statements

This news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements in this press release when it discusses estimations regarding the Company's platform's potential to reduce total healthcare costs, including by up to 10% annually; the Company's expectations regarding the potential healthcare cost savings, clinical, utilization and financial benefits of its platform and services; and the Company's expectations regarding the applicability and generalizability of the results and findings of the studies reviewed by Aon to other populations, customers and real-world settings. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

DarioHealth Corporate Contacts

Michael Lipari
SVP Corporate Development
irteam@dariohealth.com
+1-201-785-6310

Rob Halpern
SVP Marketing
irteam@dariohealth.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/dariohealth-announces-independent-aon-analysis-that-supports-estimated-2-57-2-in-year-reduction-in-total-healthcare-costs-302897540.html

SOURCE DarioHealth Corp.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much healthcare cost savings did Aon estimate for DarioHealth's platform?

Aon's review supports estimated annual savings of 2.5% to 7.2% of total healthcare spending across a covered population. For a representative 20,000-life population, that represents roughly $3.8 million to $10.8 million a year, depending on disease burden and other factors.

What did the DarioHealth component study find for users with type 2 diabetes?

The component study found $5,077 in annual savings and 23.5% fewer inpatient discharges per Dario user with type 2 diabetes compared with matched non-users.

What research methods were included in Aon's DarioHealth review?

The evidence included real-world studies using propensity score matching, a method for comparing similar participants, and randomized controlled trials conducted by Dario and third parties. The 17 studies spanned cardiometabolic, musculoskeletal and behavioral health.